Welcome to our dedicated page for Vyome Holdings SEC filings (Ticker: HIND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vyome Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vyome Holdings's regulatory disclosures and financial reporting.
Vyome Holdings, Inc. filed a Definitive Proxy Statement (DEF 14A) describing items for its annual meeting, including four proposals: the election of three Class I directors, approval of an equity Plan, ratification of the auditor, and an advisory vote on executive compensation. The filing lists nominees Krishna K. Gupta, Shiladitya Sengupta, and Stash Pomichter for three-year terms and profiles key executives including CEO Venkat Nelabhotla and CFO Robert Dickey.
The proxy explains voting mechanics for shares held in street name, noting that brokers cannot vote on certain non-routine proposals without instructions, which may lead to broker non-votes. It discloses related-party consulting payments (e.g., Dr. Sengupta: $100,000 per annum and $151,939 in VTI stock awards for 2024), director compensation retainers, stockholder proposal deadline of June 30, 2026, and prior material weaknesses in internal control reported in the Company’s Form 10-K for fiscal years 2023 and 2022.
Vyome Holdings Form 4: This Form 4 reports that Venkat Nelabhotla, President, CEO and a director, received 7 shares of Vyome Holdings common stock as a result of a merger on 08/15/2025. Under the Merger Agreement, each 5,000 shares of Vyome Therapeutics common stock converted into 1 share of Vyome Holdings common stock. The reporting person exchanged 35,000 Vyome Therapeutics shares and received 7 Vyome Holdings shares. The Form 4 was filed as a single reporting person and is signed on 09/22/2025.
John M. Tincoff III filed an initial Form 3 reporting his relationship to Vyome Holdings, Inc. (ticker shown in the filing as HIND) as a Director. The event date is 08/15/2025. The filing states no securities are beneficially owned by the reporting person. The form is signed and dated 09/18/2025.
FAQ
What is the current stock price of Vyome Holdings (HIND)?
What is the market cap of Vyome Holdings (HIND)?
